PsyBio Therapeutics Corp (CVE:PSYB) (OTCMKTS:PSYBF) CEO Evan Levine tells Proactive it has filed a provisional patent application with the US Patent and Trademark Office (USPTO), titled 'Optimized Methods for the Production of Psilocybin and its Intermediates or Side Products'.
Levine says the filing increases the company's licensed patent portfolio to four pending provisional patents and one pending non-provisional patent with the USPTO, as it builds a platform around bacterial-based synthesis of therapeutic tryptamines, a class of hallucinogens.